About AIM

AIM: Who We Are

The Aging in Motion (AIM) Coalition is a diverse group of patient, caregiver, health and aging groups working together to press for greater levels of research and innovation to develop treatments in the area of sarcopenia and age-related functional decline.

Initiated by the Alliance for Aging Research, the AIM Coalition members are leading ongoing interactions with clinicians, regulators and policy influencers to overcome obstacles that impede the development and evaluation of promising treatments for sarcopenia and associated functional decline in people as they age.

AIM members represent patients, providers, caregivers, consumers, aging Americans, researchers, employers and the health care industry. Learn more about AIM’s members.

AIM: What We Are Doing

With its diverse constituency groups and credible scientific guidance from clinical experts, AIM interacts with the scientific community, physicians who treat older patients, the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and Congressional policymakers to help improve functional strength and independence for a growing number of aging people.

Pressing for Research and Innovation

To date, no drug for the treatment or prevention of sarcopenia and functional decline has been registered or approved by the Food and Drug Administration (FDA). However,a ‘Guidance for Industry’ released by the FDA offers the possibility of a path for the pre-approval of outcome measures that could be used across a variety of treatments and therapies to establish clinically relevant indicators of functional decline or disability. Pursuing the opportunity to collaborate with the scientific community and regulators under this qualification process is one of the primary objectives of the AIM Coalition to help establish a path to safe and effective new therapies.

Coalition activities will center around raising awareness of sarcopenia, its prevalence and economic burden, and the possibilities of treatment to improve the quality of life and independence of millions of older Americans living with the condition.

AIM: Our Goals

  • Press for greater levels of research and innovation around sarcopenia and age-related functional decline.
  • Raise awareness of sarcopenia and its impact in the community
  • Increase awareness of potential for behavioral or pharmacologic interventions to improve physical function and quality of life for America’s elderly;
  • Advance consensus among clinicians and regulators on measures and outcomes to determine the efficacy of therapies specifically to treat sarcopenia and to slow functional decline;
  • Organize, lead and support a collaborative group of scientific experts to pursue the prescribed FDA qualification process for approval of outcome measures relevant for use in clinical trials of therapies that can intervene on sarcopenia and functional decline; and
  • Mobilize health care stakeholders to support the acceptance and criteria of these outcome measures for clinical use of behavioral or pharmacologic interventions, and to reimburse for such treatment.

AIM: Science Advisory Board

Board Head:
Jack M. Guralnik, M.D., Ph.D., MPH
Professor of Epidemiology and Public Health
University of Maryland, School of Medicine
Read Dr. Guralnik’s bio

Board Members:
Stephen Donahue, M.D.
Clinical Sciences,
Regeneron Pharmaceuticals

William J. Evans, Ph.D.
Executive Vice President
and President, Muscle & Health Division
KineMed
Read Dr. Evans’ bio

Luigi Ferrucci, M.D., Ph.D.
Scientific Director
National Institute on Aging
Read Dr. Ferrucci’s bio

Roger A. Fielding, Ph.D. 
Senior Scientist and Director, Nutrition, Exercise Physiology and Sarcopenia Laboratory,
Jean Mayer USDA Human Nutrition Research Center on Aging
Professor of Nutrition and Medicine, Friedman School of Nutrition Science and Policy
Tufts University School of Medicine
Read Dr. Fielding’s bio

Linda P. Fried, M.D., MPH
Dean, DeLamar Professor of Public Health, Professor of Epidemiology
Mailman School of Public Health, Columbia University
Senior Vice President
Columbia University Medical Center
Read Dr. Fried’s bio

Bret Goodpaster, Ph.D.
Senior Investigator and Professor
Translational Research Institute for Metabolism and Diabetes
Florida Hospital
Sanford Burnham Medical Research Institute
Read Dr. Goodpaster’s bio

Tamara B. Harris, M.D., M.
Laboratory of Epidemiology, Demography and Biometry
National Institute on Aging
Read Dr. Harris’ bio

Stephen Kritchevsky, Ph.D.
Director, Sticht Center on Aging,
Professor, Geriatrics & Gerontology
Wake Forest University School of Medicine
Read Dr. Kritchevsky’s bio

Jay Magaziner, Ph.D., M.S. Hyg.
Professor and Chair, Department of Epidemiology & Public Health
Director, Division of Gerontology
Co-Director, Center for Research on Aging
University of Maryland School of Medicine
Read Dr. Magaziner’s bio

Marco Pahor, M.D.
Professor and Chair, Department of Aging and Geriatric Research,
Director, Institute on Aging
University of Florida Health Science Center
Read Dr. Pahor’s bio

Ronenn Roubenoff, M.D., MHS
Head, Global Translational Medicine, Musculoskeletal Diseases
Novartis Institutes for Biomedical Research

Stephanie Studenski, M.D., MPH
Senior Investigator
Chief, Longitudinal Studies Section,
National Institutes of Health
Read Dr. Studenski’s bio

Bruno Vellas, M.D., Sc.D.
University Professor, Hospital Practitioner, Dept. of Geriatric Medicine, Univ. Hosp. Center, Toulouse, Purpan
Faculty of Medicine, University Paul Sabatier, Toulouse, France
Research Associate Professor, Clinical Nutrition Laboratory, University of New Mexico School of Medicine